Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03317730 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer
A Early Phase 1 study of Locally Advanced Head and Neck Cancer, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03317730 is a Early Phase 1 study of Locally Advanced Head and Neck Cancer that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03317730, a Early Phase 1 study of Locally Advanced Head and Neck Cancer, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
To confirm the feasibility of studying Xtampza ER during radiotherapy (RT) for LAHNC as part of a prospective clinical trial.
Conditions Studied
Interventions
- DRUG Xtampza ER
Study Locations (1)
Alabama
- Hazelrig-Salter Radiation Oncology Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2020-11-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03317730
The ClinicalTrials.gov registry entry for NCT03317730 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Xtampza ER is the first listed.
NCT03317730 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03317730 about?
NCT03317730 is a clinical study titled "Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer". To confirm the feasibility of studying Xtampza ER during radiotherapy (RT) for LAHNC as part of a prospective clinical trial.
What is the current status of trial NCT03317730?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2018-05-01. Estimated completion is 2020-11-17.
What conditions does trial NCT03317730 study?
This clinical trial studies the following conditions: Locally Advanced Head and Neck Cancer.
What interventions are being tested in trial NCT03317730?
The interventions under investigation include: Xtampza ER (DRUG).
Who is sponsoring clinical trial NCT03317730?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03317730 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.